CAJ | 학술논문

转移性乳腺癌（MBC）患者普遍使用蒽环类和紫杉烷类药物治疗，但部分患者对紫杉烷类药物过敏，还有一些患者在治疗后对紫杉烷类产生耐药性，病症会在短期内迅速复发。对于这些患者，很难找到其他有效治疗方案。伊沙匹隆作为新一代微管抑制剂类抗肿瘤药物在对蒽环类和紫杉烷类药物耐药的MBC患者的治疗中作用显著，现对伊沙匹隆的药理学和临床方面的研究进行综述。
전이성유선암（MBC）환자보편사용은배류화자삼완류약물치료，단부분환자대자삼완류약물과민，환유일사환자재치료후대자삼완류산생내약성，병증회재단기내신속복발。대우저사환자，흔난조도기타유효치료방안。이사필륭작위신일대미관억제제류항종류약물재대은배류화자삼완류약물내약적MBC환자적치료중작용현저，현대이사필륭적약이학화림상방면적연구진행종술。
Generally, anthracyclines and taxanes are applied to treat metastatic breast cancer (MBC) as chemotherapeutic agents. However, some patients are over-sensitive to taxanes, or experience rapid relapse due to resistance to taxanes, for whom, anthracyclines and taxanes have poor therapentic efficacy. Fortunately, ixabepilone, a novel microtubules inhibitor, exerts great effects on MBC patients who are resistant to anthracyclines and taxanes. In this article, we reviewed the pharmacology of ixabepilone and its progress in clinical research.